Baideng Medical Secures RMB 100 Million Series A+ Funding to Become the 'New Chain Leader' in China's Medical Device Distribution Industry

On May 22, China’s largest B2B e-commerce platform for medical devices—Beideng MedicalDisclosed to VCBeat, the company hasCompleted a RMB 100 million Series A+ financing round, led by Yuanyi Capital, with participation from Jiequan Zhongwei and Oriental Fortune Capital, and Life Capital serving as the financial advisor.

This round of funding will be primarily used to strengthen the e-commerce platform, reinforce Beden Medical's absolute leading position in China's B2B medical device industry, and build a medical distribution ecosystem.Positioning Beideng Medical as the “New Chain Leader” of China’s Medical Device Distribution Industry Chain。

Beden Medical's Historical Financing

In recent years, driven by policy support and capital investment, China’s medical device industry has entered a phase of rapid growth, with a compound annual growth rate (CAGR) exceeding 20%. In 2016, the end-user procurement volume for medical devices in China surpassed RMB 600 billion, and it is projected to exceed RMB 1 trillion by 2020.

In such a vast market, there are 15,000 manufacturers, 180,000 distributors, and 1 million medical institutions. The entire industrial chain is highly fragmented both upstream and downstream, characterized by being “numerous, small, scattered, and disordered.” In particular, the intermediate distribution segment has relied on the traditional distributor agency model for over two decades, resulting in fragmented channels and dependence on “relationship-based sales,” which has led to extremely low circulation efficiency in the industry.

More importantly, in recent years, China’s medical device industry has undergone significant changes across the entire value chain—from upstream R&D and manufacturing, through midstream distribution channels, to downstream healthcare institutions. Reform of China’s medical device distribution channels is imminent.

First, the state encourages innovation in medical devices, leading many overseas Chinese to return home and start businesses, resulting in a continuous increase in emerging medical device enterprises. Second, as the world’s second-largest medical device market after the United States, China has attracted numerous foreign companies aiming to capture this significant market share by establishing branches in the country.

Competition in China’s medical device industry is intensifying, placing immense pressure on manufacturers to transform their sales channels. They must reconstruct their entire marketing channel systems to rapidly penetrate the market and reach a broader base of target customers. Established manufacturers require new channels to cover emerging and underserved markets, while emerging manufacturers need nationwide channels to achieve comprehensive customer coverage quickly.

“Today, if an innovative medical device company fails to rapidly penetrate the market within two to three years after obtaining marketing authorization, it will unfortunately find itself overtaken by a wave of competitors. Technological leadership is transient; what matters more are your marketing and commercial capabilities,” said Ding Haibo, CEO of Beden Medical.

In addition, the landscape of downstream medical institutions has undergone significant changes, with a surge in emerging private entities such as third-party medical institutions, physician groups, specialized chain clinics, health examination centers, and veterinary hospitals.

Data shows that since 2014, more than 90% of newly established medical institutions annually have been concentrated in the primary care and private healthcare sectors. It is projected that by 2020, the combined market share of private medical institutions and public primary care facilities in China will exceed 50%. These emerging primary care and private medical institutions have undoubtedly become the key growth markets for medical device manufacturers.

However, as private institutions pursue diversified development, they have raised higher demands on suppliers in areas such as financial services, IT-enabled services, and after-sales support. The upgrading of procurement practices in healthcare institutions will inevitably lead to elevated requirements for suppliers.

So, in the face of a large number of emerging medical markets and untapped markets, how can medical device manufacturers reform their marketing channels to meet the “market-oriented procurement” needs of emerging medical institutions?

Clearly, the traditional channel model is no longer viable.

In Ding Haibo’s view, the traditional sales model for medical devices in China relies heavily on personal relationships (guanxi), while professional expertise, technical support capabilities, and financial strength are relatively weak. It is difficult for these distributors to drive transformation across the entire distribution channel as healthcare institutions upgrade their procurement processes, because their inherent business DNA precludes them from having the capability to undertake such upgrades.

Therefore, driven by the immense pressure on upstream manufacturers to transform their sales and distribution channels, the demand from downstream medical institutions for procurement upgrades, and the impact of policies such as the “Two-Invoice System” and anti-corruption initiatives, China’s medical device distribution industry urgently requires new, more efficient, and capable distribution service providers to drive comprehensive industrial transformation.

Beideng Medical, as China’s largest B2B e-commerce platform for medical devices, has seized the opportunities brought about by industry transformation.

Addressing pain points such as the fragmentation and relationship-driven sales model of traditional channel distributors, the lack of nationwide sales channels for upstream manufacturers, and the shortage of high-quality distribution channels and technical support for downstream hospitals, the company leverages the power of the internet to provide a nationwide one-stop sales and procurement platform for manufacturers, distributors, and hospitals.

According to Ding Haibo, Beideng Medical was established in 2010 as a self-operated e-commerce platform similar to JD.com. By deeply integrating upstream and downstream resources in the medical device industry, it has built a new type of B2B distribution platform for medical devices, aiming to improve transaction efficiency and reduce costs within the sector.

To date, Beden Medical has established partnerships with more than 300 upstream medical device manufacturers, including Mindray, Wandong, Yuwell, Xinhua, Qianjing, Omron, and Sinocare. The platform offers over 20,000 SKUs, demonstrating robust product supply capabilities.

Meanwhile, Beideng Medical also directly serves a vast downstream network of distributors and end-user private medical institutions. It has accumulated over 100,000 distributor members, partnered with more than 10,000 distributors, and collaborated with over 3,000 private medical institutions, covering more than 300 prefecture-level cities across China.

Such a robust customer database is precisely where Beden Medical’s value lies. By establishing databases of products, manufacturers, distributors, and end-users, the company captures procurement demands, helps clients achieve precision marketing, and boosts transaction rates across the entire industry.

For example, by analyzing manufacturer and product data, Beden can help clients identify similar products. It is possible to ascertain which brands have been best-sellers in recent years, through which distributors they were channeled, to which medical institutions they were sold, and even their pricing information.

Undoubtedly, Beideng Medical’s model has brought significant benefits to small-scale manufacturers, distributors, and some small clinics and private hospitals, while offering immense potential for the future realization of “completely eliminating intermediaries and implementing a single-invoice system directly to end-user hospitals.”

According to Ding Haibo, following the completion of this financing round, the company’s primary plan is to solidify its e-commerce platform and reinforce Beden Medical’s absolute leading position in China’s medical device B2B industry.

Ding Haibo, CEO of Beden Medical

The company will comprehensively upgrade its three core capabilities: channel capabilities, supply chain capabilities, and internet capabilities.

●  Channel CapabilitiesBy the end of 2018, the company had established a network of over 150,000 distributor members, collaborated with more than 20,000 partners, and covered county/district-level medical markets in over 2,500 locations across China.

Meanwhile, Baiden Medical will directly serve more than 5,000 new chain private medical institutions. Through collaboration with O2O platforms and industry traffic partners, it will achieve coverage of hundreds of thousands of independent private hospitals and clinics, establishing itself as the most competitive sales channel in China’s public primary healthcare and private medical markets.

● Supply Chain CapabilitiesAdhering to the principle of “comprehensive categories and curated brands,” the company will, on one hand, strengthen strategic cooperation with existing leading brands by deepening engagement and expanding scope; on the other hand, it will continuously introduce new products from emerging leading brands to enhance the category and pricing advantages of the Beideng e-commerce platform.

Meanwhile, Beden Medical will establish additional regional and local warehousing centers to enable rapid delivery and provide customers with more robust supply chain services.

● Internet CapabilitiesIn this regard, VCBeat will comprehensively upgrade its internet products, digital strategies, and internet talent.

First, targeting different customer segments and centering on “customer-centric operations,” we will strategically upgrade Baideng’s internet products and IT capabilities to improve service efficiency, enhance the procurement experience, and strengthen customer stickiness.

Secondly, comprehensively upgrade the entire internet strategy across the full customer lifecycle: “Acquisition – Information Delivery – Transaction – Service – Retention – Engagement.”

Finally, further upgrade Bedeng’s internet talent pool: on one hand, rapidly upskill existing staff, while on the other, recruit more outstanding internet operations professionals to build a more robust and powerful talent pipeline.

Upon completion of this round of financing,Beideng Medical has set a new goal: to become the “new chain leader” of China’s medical device distribution industry chain within three years.

In fact, since the second half of 2017, Beideng Medical has made in-depth strategic investments across the medical device distribution industry chain, gradually building competitive advantages within its ecosystem.

The company aims to center its strategy on a self-operated B2B e-commerce platform, continuously strengthening the integration of product resources from over a thousand upstream medical device manufacturers and enhancing coverage and services for downstream channels, including 100,000 distributors and 200,000 private healthcare institutions.Rapidly become the new gateway for online procurement and sales of medical devices in China.

Additionally, over a period of approximately two years, we will gradually establish localized service teams covering all 31 provinces in China, build an integrated online and offline service system, and enhance our service capabilities for both upstream and downstream partners.At that time, Beden Medical will be"The only new-type medical device distributor in China with both nationwide multi-channel online sales coverage and nationwide local service capabilities."

In fact, beyond its B2B e-commerce platform and O2O service network, Beideng’s medical distribution ecosystem value network has gradually incubated, acquired, and integrated many key modules, includingNew Media Marketing, National After-Sales Service Network, Regional Warehousing Centers, Supply Chain Finance, Medical Procurement SaaS, Niche B2B E-commerce Platforms, Cross-Border E-commerce for Medical Devicesetc.

Ding Haibo stated that each individual module, if well-developed, would hold significant industry value and competitiveness. By integrating these modules into a comprehensive value network where they synergize and support one another, Beden has not only established a formidable competitive moat but also enhanced the collaborative value it delivers to upstream and downstream partners.

For example, the new media marketing platform for the medical device industry within the Beden ecological network has incubated over a dozen leading new media channels in niche product categories or clinical specialties, accumulating a total of nearly 1 million followers. It has already assisted nearly one hundred medical device manufacturers in conducting precise mobile marketing. These new media channels serve not only as Beden’s media platforms but also as significant sources of traffic.

Furthermore, Beideng has integrated more than 5,000 local medical device maintenance engineers and, drawing on the Didi Chuxing model, built a nationwide after-sales service network to improve manufacturers’ repair efficiency and reduce their maintenance costs.

Finally, Ding Haibo also revealed to VCBeat that the companyThe 2018 goal was to become a new type of B2B e-commerce platform for medical devices, driven by technology, data, and supply chain capabilities, with ecosystem-level competitiveness.

He stated, “Over the past few years of entrepreneurship in the healthcare sector, although Beden’s business model has undergone continuous iteration, our original aspiration has remained unchanged. Beden’s development has always revolved around our mission and vision. Beden’s mission is to leverage the internet to transform the traditional distribution model of medical devices.”Making Medical Device Procurement Easier, and Baiden’s vision is to become the world’s largest healthcare e-commerce platform.”

Investors have also expressed great satisfaction with the achievements made by Beden Medical in recent years.

Gao Yi, a partner at YuanYi Capital, the lead investor in this funding round, believes that behind Beideng Medical’s success lies a profound transformation in the structure of the entire healthcare services market. This change has been driven by the rapid rise of primary care and general practice institutions—such as private hospitals, specialized clinic chains, and third-party independent medical facilities—as well as the sustained incentives provided by multiple policies with clear strategic directions.

For the medical device industry, the emerging private and primary healthcare markets have distinctly different demands from the existing distribution model centered on public tertiary hospitals, whether in terms of product preferences, procurement models, supply chain management, data and informatization, or value-added technology and services. Channel innovation is therefore imperative.

“Bedeng’s business model, iterative capabilities, and ecosystem align well with this rapidly growing market. We are highly optimistic about the strong execution team led by Mr. Ding Haibo, which is poised to build a new type of distribution channel driven by technology and data, with value-added services and supply chain management as its core competencies. This will enable Bedeng to fulfill its original aspiration, mission, and vision, thereby completing the full landscape of China’s medical device distribution sector.”said Gao Yi.

Yuan Yi Capital is an international venture capital fund, with its inaugural funds comprising a U.S. dollar fund and a Renminbi fund, focusing on early- and growth-stage enterprises in the healthcare and innovative financial technology sectors.

Yuan Yi Capital is committed to identifying the most innovative stars of tomorrow on a global scale through in-depth, continuous industry research and by leveraging support from world-class industry experts. By capitalizing on the significant opportunities arising from market reforms, the firm focuses on corporate growth, team quality, and core competitiveness, thereby substantially enhancing the strategic, operational, market expansion, and international cooperation capabilities of its portfolio companies.